Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18002710 | 0.86 | AHR (0.53) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18002544 | 0.86 | NFE2L2 (0.59) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL16406667 | 0.86 | NFE2L2 (0.59) | NFE2L2PTGS1PTGS2ALOX5CYP17A1 | |
| SCHEMBL3673867 | 0.84 | NFE2L2 (0.64) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL3673865 | 0.84 | NFE2L2 (0.64) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL6464939 | 0.84 | NFE2L2 (0.64) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18002822 | 0.83 | CYP1A1 (0.46) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18002818 | 0.82 | NQO2 (0.77) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18144278 | 0.82 | NFE2L2 (0.62) | NFE2L2PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL18144277 | 0.82 | NFE2L2 (0.62) | NFE2L2PTGS1PTGS2NQO2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NFE2L2 1380/4885PTGS1 2094/4885PTGS2 2928/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NFE2L2 1380/4885PTGS1 2094/4885PTGS2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.